Cargando…
Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment
BACKGROUND: The role of n-3 polyunsaturated fatty acids (PUFAs) in breast cancer is not clear and under debate. To explore this relationship it is important to have proper validated dietary assessment methods for measuring the intake of n-3 PUFAs. The aim of the current study is to validate two diff...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192340/ https://www.ncbi.nlm.nih.gov/pubmed/30333016 http://dx.doi.org/10.1186/s12937-018-0402-6 |
_version_ | 1783363891374325760 |
---|---|
author | Brunvoll, Sonja H. Thune, Inger Frydenberg, Hanne Flote, Vidar G. Bertheussen, Gro F. Schlichting, Ellen Bjerve, Kristian S. Hjartåker, Anette |
author_facet | Brunvoll, Sonja H. Thune, Inger Frydenberg, Hanne Flote, Vidar G. Bertheussen, Gro F. Schlichting, Ellen Bjerve, Kristian S. Hjartåker, Anette |
author_sort | Brunvoll, Sonja H. |
collection | PubMed |
description | BACKGROUND: The role of n-3 polyunsaturated fatty acids (PUFAs) in breast cancer is not clear and under debate. To explore this relationship it is important to have proper validated dietary assessment methods for measuring the intake of n-3 PUFAs. The aim of the current study is to validate two different methods used to assess the intake of selected n-3 PUFAs as well as food sources of long-chained n-3 PUFAs. Also, we aim to study how stable the intake of fatty acids is during breast cancer treatment. METHODS: The study-population was patients with breast cancer (Stages I-II) or ductal carcinoma in situ (DCIS-grade III) undergoing treatment (n = 49) in Norway. Dietary intake was assessed by two self-administered methods, a 256 food item food frequency questionnaire (FFQ) and a 7-day pre-coded food diary (PFD). The FFQ was administered presurgery and twelve months postsurgery, and the PFD was administered shortly after surgery (10 +/− 2 days), six and twelve months postsurgery. Fasting blood samples (presurgery, six and twelve months postsurgery) were analysed for serum phospholipid fatty acids, a biomarker for intake of n-3 PUFAs. RESULTS: Mean (SD) age was 54.2 (7.8) years at diagnosis, and the mean (SD) body mass index (BMI) was 24.8 (3.4) kg/m(2). Correlation coefficients between dietary intakes of n-3 PUFAs measured with the FFQ and the PFD ranged from 0.35 to 0.66. The correlation coefficients between the PFD and the biomarker (serum phospholipid n-3 PUFAs) as well as between the FFQ and the biomarker demonstrated stronger correlations twelve months after surgery (ρ 0.40–0.56 and 0.36–0.53, respectively) compared to around surgery (ρ 0.08–0.20 and 0.28–0.38, respectively). The same pattern was observed for intake of fatty fish. The intake of n-3 PUFAs did not change during treatment assessed by the FFQ, PFD or biomarker. CONCLUSION: These results indicate that the FFQ and the PFD can be used to assess dietary intake of fish and n-3 PUFAs in breast cancer patients during breast cancer treatment. Still, the PFD shortly after surgery should be used with caution. The diet of patients undergoing breast cancer treatment was quite stable, and the intake of n-3 PUFAs did not change. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12937-018-0402-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6192340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61923402018-10-22 Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment Brunvoll, Sonja H. Thune, Inger Frydenberg, Hanne Flote, Vidar G. Bertheussen, Gro F. Schlichting, Ellen Bjerve, Kristian S. Hjartåker, Anette Nutr J Research BACKGROUND: The role of n-3 polyunsaturated fatty acids (PUFAs) in breast cancer is not clear and under debate. To explore this relationship it is important to have proper validated dietary assessment methods for measuring the intake of n-3 PUFAs. The aim of the current study is to validate two different methods used to assess the intake of selected n-3 PUFAs as well as food sources of long-chained n-3 PUFAs. Also, we aim to study how stable the intake of fatty acids is during breast cancer treatment. METHODS: The study-population was patients with breast cancer (Stages I-II) or ductal carcinoma in situ (DCIS-grade III) undergoing treatment (n = 49) in Norway. Dietary intake was assessed by two self-administered methods, a 256 food item food frequency questionnaire (FFQ) and a 7-day pre-coded food diary (PFD). The FFQ was administered presurgery and twelve months postsurgery, and the PFD was administered shortly after surgery (10 +/− 2 days), six and twelve months postsurgery. Fasting blood samples (presurgery, six and twelve months postsurgery) were analysed for serum phospholipid fatty acids, a biomarker for intake of n-3 PUFAs. RESULTS: Mean (SD) age was 54.2 (7.8) years at diagnosis, and the mean (SD) body mass index (BMI) was 24.8 (3.4) kg/m(2). Correlation coefficients between dietary intakes of n-3 PUFAs measured with the FFQ and the PFD ranged from 0.35 to 0.66. The correlation coefficients between the PFD and the biomarker (serum phospholipid n-3 PUFAs) as well as between the FFQ and the biomarker demonstrated stronger correlations twelve months after surgery (ρ 0.40–0.56 and 0.36–0.53, respectively) compared to around surgery (ρ 0.08–0.20 and 0.28–0.38, respectively). The same pattern was observed for intake of fatty fish. The intake of n-3 PUFAs did not change during treatment assessed by the FFQ, PFD or biomarker. CONCLUSION: These results indicate that the FFQ and the PFD can be used to assess dietary intake of fish and n-3 PUFAs in breast cancer patients during breast cancer treatment. Still, the PFD shortly after surgery should be used with caution. The diet of patients undergoing breast cancer treatment was quite stable, and the intake of n-3 PUFAs did not change. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12937-018-0402-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-17 /pmc/articles/PMC6192340/ /pubmed/30333016 http://dx.doi.org/10.1186/s12937-018-0402-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Brunvoll, Sonja H. Thune, Inger Frydenberg, Hanne Flote, Vidar G. Bertheussen, Gro F. Schlichting, Ellen Bjerve, Kristian S. Hjartåker, Anette Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title | Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title_full | Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title_fullStr | Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title_full_unstemmed | Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title_short | Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
title_sort | validation of repeated self-reported n-3 pufa intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192340/ https://www.ncbi.nlm.nih.gov/pubmed/30333016 http://dx.doi.org/10.1186/s12937-018-0402-6 |
work_keys_str_mv | AT brunvollsonjah validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT thuneinger validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT frydenberghanne validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT flotevidarg validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT bertheussengrof validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT schlichtingellen validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT bjervekristians validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment AT hjartakeranette validationofrepeatedselfreportedn3pufaintakeusingserumphospholipidfattyacidsasabiomarkerinbreastcancerpatientsduringtreatment |